key: cord-0745532-3oc3mfrr authors: Romero-Gameros, Carlos Alfonso; Vargas-Ortega, Guadalupe; Rendón-Macias, Mario Enrique; Cuevas-García, Carlos Fredy; Colín-Martínez, Tania; Sánchez-Hurtado, Luis Alejandro; Balcázar-Hernández, Lourdes Josefina; De la Cruz-Rodríguez, Iván Emilio; Pérez-Dionisio, Enid Karina; Retana-Torres, Perla Michelle; García-Montesinos, Elsy Sarahí; López-Moreno, Mayra Alejandra; Intriago-Alor, Marielle; Waizel-Haiat, Salomón; González-Virla, Baldomero title: Risk Factors Associated with Mortality among Patients with COVID-19: Analysis of a Cohort of 1213 Patients in a Tertiary Healthcare Center date: 2022-05-14 journal: J Clin Med DOI: 10.3390/jcm11102780 sha: 143b8cdb1c3993cb1556b1a7f06f988624c21c6a doc_id: 745532 cord_uid: 3oc3mfrr The presence of cardio-metabolic and respiratory comorbidities, immunosuppression, and chronic kidney disease have been associated with an increase in mortality from COVID-19. The objective of this study is to establish the risk factors associated with 30-day mortality in a cohort of hospitalized patients with COVID-19. This paper conducts a retrospective and analytical study of patients hospitalized for COVID-19 in a tertiary care center. A Cox proportional hazard analysis was performed to estimate the association of comorbidities with 30-day mortality. A total of 1215 patients with a median age of 59 years were included. In the adjusted Cox proportional hazards regression model, hypothyroidism, D-dimer ≥ 0.8 μg/mL, LHD ≥ 430 IU/L, CRP ≥ 4.83 ng/mL, and triglycerides ≥ 214 mg/dL were associated with an increased risk of death. The presence of a history of hypothyroidism and biomarkers (D-dimer, lactic dehydrogenase, CRP, and triglycerides) were associated with an increase in mortality in the studied cohort. The COVID-19 pandemic, caused by the SARS-CoV-2 virus infection, began in the Wuhan region of China in late 2019 and reached Mexico in February 2020, with a frenzied increase during the following months. The SARS-CoV-2 infection was mainly characterized by acute respiratory symptoms and related systemic complications. The presence of cardio-metabolic (diabetes, hypertension, and obesity) and respiratory (asthma and chronic obstructive pulmonary disease) comorbidities, immunosuppression, and chronic kidney J. Clin. Med. 2022, 11, 2780 2 of 11 disease (CKD) were all aggravating factors in the evolution and possible triggers for increased mortality in Mexico [1] [2] [3] [4] [5] . Bello-Chavolla et al. conducted a study within a Mexican sample where they investigated the specific risk factors associated with mortality, in particular the impact of diabetes and obesity on lethality in COVID-19 patients. Their results showed a higher risk of death after 30 days in patients with the following description: over 65 years old, diabetes mellitus 2 (DM2), obesity, CKD, chronic obstructive pulmonary disease (COPD), immunosuppression, and hypertension [3] . At the time of writing this manuscript (May 6th, 2022), 516,326,823 cases have been recorded worldwide, with a total of 6,248,434 deaths. In Mexico, the figure has reached 5,739,680 cases and 324,334 deaths, representing a case fatality rate of 1.21% and 5.65%, respectively [6] . This fatality rate could be higher amongst high-risk populations with a greater number of comorbidities. Although there are numerous reports in the Mexican population and in the world on various clinical and biochemical risk factors associated with the risk of mortality in patients with SARS-CoV-2 infection, a high-risk analysis will allow us to understand this phenomenon with greater precision. Thus, the aim of this study is to establish the risk factors (clinical characteristics, comorbidities, and other predictors) associated with a 30-day mortality in a cohort of patients hospitalized due to COVID-19 in a tertiary care center where the prevalence of comorbidities was more pronounced. An observational, retrospective, and analytical study was conducted among COVID-19 patients at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (a tertiary center) in Mexico City, Mexico, during the period between 1 March 2020 and 30 May 2021. Patients were included using the following criteria: ≥18 years old, with a COVID-19 diagnosis confirmed by RT-PCR, of any gender, and with complete labs for the purposes of the study. The primary outcome was death from COVID-19 and its complications within 30 days of hospital admission. The death certificates of 243 patients of the studied cohort were obtained. The present study was approved by the local ethics and research committee (Registry identifier: R-2020-3601-245) and was consistent with the ethical guidelines of the 1975 Helsinki Declaration and the Mexican General Health Law on Research for Health Studies. Data were collected retrospectively through consultation of the electronic clinical records. The demographic data, comorbidities, symptomatology at admission, laboratory results, and therapies used were all collected. The identification of SARS-CoV-2 was obtained by real-time RT-PCR in nasopharyngeal exudate samples processed at the Central Epidemiology Laboratory of the National Medical Center "La Raza" of the Mexican Social Security Institute, following international standards for infectious substances. Co-morbidities were defined as follows: a chronic obstructive pulmonary disease (COPD) diagnosis of a postbronchodilator FEV1/FVC ratio around <0.70 [7] ; asthma according to the Global Initiative for Asthma 2020 criteria [8] ; heart disease as a diagnosis of coronary artery disease, congestive heart failure, or heart rhythm problems; CKD as a glomerular filtration rate below 60 mL/min [9] ; immunodeficiency disease as the diagnosis of any immunodeficiency disorder, whether primary or secondary; diabetes as a fasting plasma glucose (FPG) level of 126 mg/dL or higher, a 2 h plasma glucose level of 200 mg/dL or higher during a 75-g oral glucose tolerance test, or a hemoglobin A1c level of 6.5% or higher [10] ; hypertension as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg [11] ; and primary hypothyroidism as a TSH level > 4.2 µIU/mL and T4 level < 0.93 ng/dL, and in the case of central hypothyroidism, a T4 level < 0.8 ng/dL. Analysis for detecting serum glucose, d-dimer, lactic dehydrogenase, ferritin, creactive protein, and triglycerides were performed in the laboratory of the Hospital de Especialidades Centro Médico Nacional Siglo XXI. Samples for laboratory analysis were obtained at the time of hospital admission. The treatments used at the hospital were classified as: immunomodulatory therapy (systemic corticosteroids or tocilizumab), antimicrobial therapy (macrolide, quinolones, beta-lactam, hydroxychloroquine, azithromycin, or lopinavir/ritonavir), or anticoagulant therapy (low-molecular-weight heparin). Descriptive and inferential statistics were used for data analysis, taking into account measures of central trends and dispersion. The chi-square test was used to compare frequencies and proportions. The Mann-Whitney U test or Student's t test was used to compare quantitative variables. The Shapiro-Wilk test was used to determine the normality of the distribution of the variables. A receiver operating characteristic (ROC) analysis was performed to determine the best cutoff points for the following continuous quantitative variables: age, D-dimer, LDH, ferritin, CRP, and triglycerides. To determine the best cut-off points, sensitivity, specificity, accuracy, and likelihood ratio (LR)+ and LR-were taken into account. A Cox proportional hazard analysis was performed to estimate the magnitude of the relationship between the different COVID-19-associated comorbidities (and biochemical parameters) and mortality during the 30 days after admission. The variables included in the regression model were made taking into account biological plausibility and statistical significance. A Kaplan-Meier plot was used to estimate the probability of survival at 30 days after hospitalization, while the log-rank test was used to compare the difference in survival probability for different groups of COVID-19 patients. A two-sided p value was used for the in-between group difference with respect to the primary outcome. A p value of p < 0.05 was considered statistically significant. The statistical software used was SPSS version 25.0 (IBM SPSS Statistics for Windows, IBM Corp, Armonk, NY, USA), Stata SE software version 16 (StataCorp, College Station, TX, USA), and GraphPad Prism version 8.0 for Windows (GraphPad Software, San Diego, CA, USA). During the study period, 2074 patients were hospitalized with suspected COVID-19, out of whom 1215 met our criteria for mortality risk analysis ( Figure 1 ). The number of deaths recorded was 653 (53.7%). The median age for the total study population was 59 years (IQR, 47-69 years). The median age in the group of patients who died was 63 years (IQR, 52-72 years) vs. 54 years (IQR, 43-66 years), with a difference of 9 years (95% CI; 6-11 years) between the two groups. Of the total group, 764 patients (62.8%) were male, with similar proportions between non-survivors (NS) and survivors (Table 1 ). The median age for the total study population was 59 years (IQR, 47-69 years). The median age in the group of patients who died was 63 years (IQR, 52-72 years) vs. 54 years (IQR, 43-66 years), with a difference of 9 years (95% CI; 6-11 years) between the two groups. Of the total group, 764 patients (62.8%) were male, with similar proportions between non-survivors (NS) and survivors (Table 1) . In the group of patients studied, the presence of fever and dyspnea was significantly more frequent than in the group of non-survivors (Table 1) . Regarding biomarkers, statistically significant differences were observed in the concentrations of fasting plasma glucose, D-dimer, LDH, ferritin, CRP, and triglycerides when comparing both groups (see Table 1 ). Similarly, a higher proportion of type 2 diabetes (T2D), hypertension, liver disease, and hypothyroidism was observed in the non-survivor group, reaching statistical significance ( Table 1) . The proportion of patients with ≥2 comorbidities was significantly higher in the non-survivor group than in the survivor group. (See Table 1 ). The cut-off points of the different continuous quantitative variables and their respective sensitivity, specificity, accuracy, LR+, and LR−, are presented below: D-dimer ≥ 0. 8 In the adjusted Cox proportional hazards regression model, hypothyroidism, D-dimer ≥ 0.8 µg/mL, LDH ≥ 430 IU/L, CRP ≥ 4.83 ng/mL, and triglycerides ≥ 214 mg/dL were significantly associated with an increased risk of death (Table 2, Figure 2 ). For the Cox proportional hazards model, a chi2 LR of 91.74 was obtained with a p value < 0.001. Figure 2 ). The Kaplan-Meier analysis showed that the probability of 30-day survival in hospitalized patients ≥65 years was 11% vs. 20% in those <65 years; survival in patients with hypertension was 12% vs. 18% in those without hypertension; and survival in patients with ≥two comorbidities was 12% vs. 19% in patients with